Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone.

Halevy O, Genin O, Barzilai-Tutsch H, Pima Y, Levi O, Moshe I, Pines M.

Histol Histopathol. 2013 Feb;28(2):211-26. doi: 10.14670/HH-28.211.

PMID:
23275304
2.

Halofuginone promotes satellite cell activation and survival in muscular dystrophies.

Barzilai-Tutsch H, Bodanovsky A, Maimon H, Pines M, Halevy O.

Biochim Biophys Acta. 2016 Jan;1862(1):1-11. doi: 10.1016/j.bbadis.2015.10.007. Epub 2015 Oct 8.

3.

Fibrosis inhibition and muscle histopathology improvement in laminin-alpha2-deficient mice.

Nevo Y, Halevy O, Genin O, Moshe I, Turgeman T, Harel M, Biton E, Reif S, Pines M.

Muscle Nerve. 2010 Aug;42(2):218-29. doi: 10.1002/mus.21706.

PMID:
20589893
4.

Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone.

Turgeman T, Hagai Y, Huebner K, Jassal DS, Anderson JE, Genin O, Nagler A, Halevy O, Pines M.

Neuromuscul Disord. 2008 Nov;18(11):857-68. doi: 10.1016/j.nmd.2008.06.386. Epub 2008 Jul 30.

PMID:
18672370
5.

Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone.

Huebner KD, Jassal DS, Halevy O, Pines M, Anderson JE.

Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1550-61. doi: 10.1152/ajpheart.01253.2007. Epub 2008 Feb 8.

6.

Halofuginone and muscular dystrophy.

Pines M, Halevy O.

Histol Histopathol. 2011 Jan;26(1):135-46. doi: 10.14670/HH-26.135. Review.

PMID:
21117034
7.

Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention.

Zion O, Genin O, Kawada N, Yoshizato K, Roffe S, Nagler A, Iovanna JL, Halevy O, Pines M.

Pancreas. 2009 May;38(4):427-35. doi: 10.1097/MPA.0b013e3181967670.

PMID:
19188864
8.

Halofuginone improves muscle-cell survival in muscular dystrophies.

Bodanovsky A, Guttman N, Barzilai-Tutsch H, Genin O, Levy O, Pines M, Halevy O.

Biochim Biophys Acta. 2014 Jul;1843(7):1339-47. doi: 10.1016/j.bbamcr.2014.03.025. Epub 2014 Apr 2.

9.

Focusing on fibrosis: halofuginone-induced functional improvement in the mdx mouse model of Duchenne muscular dystrophy.

McLoon LK.

Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1505-7. doi: 10.1152/ajpheart.00176.2008. Epub 2008 Feb 29. No abstract available.

10.

Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: effect on myotube fusion.

Roffe S, Hagai Y, Pines M, Halevy O.

Exp Cell Res. 2010 Apr 1;316(6):1061-9. doi: 10.1016/j.yexcr.2010.01.003. Epub 2010 Jan 11.

PMID:
20060825
11.
12.

Lipid accumulation in dysferlin-deficient muscles.

Grounds MD, Terrill JR, Radley-Crabb HG, Robertson T, Papadimitriou J, Spuler S, Shavlakadze T.

Am J Pathol. 2014 Jun;184(6):1668-76. doi: 10.1016/j.ajpath.2014.02.005. Epub 2014 Mar 29.

PMID:
24685690
13.

Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy.

Lee YS, Lehar A, Sebald S, Liu M, Swaggart KA, Talbot CC Jr, Pytel P, Barton ER, McNally EM, Lee SJ.

Hum Mol Genet. 2015 Oct 15;24(20):5711-9. doi: 10.1093/hmg/ddv288. Epub 2015 Jul 23.

14.

Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma.

Pines M, Snyder D, Yarkoni S, Nagler A.

Biol Blood Marrow Transplant. 2003 Jul;9(7):417-25. Review.

15.

Dysferlinopathy Promotes an Intramuscle Expansion of Macrophages with a Cyto-Destructive Phenotype.

Baek JH, Many GM, Evesson FJ, Kelley VR.

Am J Pathol. 2017 Jun;187(6):1245-1257. doi: 10.1016/j.ajpath.2017.02.011. Epub 2017 Apr 13.

PMID:
28412297
16.

Halofuginone ameliorates autoimmune arthritis in mice by regulating the balance between Th17 and Treg cells and inhibiting osteoclastogenesis.

Park MK, Park JS, Park EM, Lim MA, Kim SM, Lee DG, Baek SY, Yang EJ, Woo JW, Lee J, Kwok SK, Kim HY, Cho ML, Park SH.

Arthritis Rheumatol. 2014 May;66(5):1195-207. doi: 10.1002/art.38313.

17.

A promotive effect for halofuginone on membrane repair and synaptotagmin-7 levels in muscle cells of dysferlin-null mice.

Barzilai-Tutsch H, Dewulf M, Lamaze C, Butler Browne G, Pines M, Halevy O.

Hum Mol Genet. 2018 Aug 15;27(16):2817-2829. doi: 10.1093/hmg/ddy185.

PMID:
29771357
18.

Elevated Expression of Moesin in Muscular Dystrophies.

Pines M, Levi O, Genin O, Lavy A, Angelini C, Allamand V, Halevy O.

Am J Pathol. 2017 Mar;187(3):654-664. doi: 10.1016/j.ajpath.2016.11.013. Epub 2017 Jan 9.

PMID:
28082118
19.

Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo.

Gross DJ, Reibstein I, Weiss L, Slavin S, Dafni H, Neeman M, Pines M, Nagler A.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3788-93.

20.

Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats.

Bruck R, Genina O, Aeed H, Alexiev R, Nagler A, Avni Y, Pines M.

Hepatology. 2001 Feb;33(2):379-86.

PMID:
11172339

Supplemental Content

Support Center